【レポートの概要（一部）】
Table of Content
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Autoimmune and inflammatory diseases
• Rheumatoid arthritis
• IBD
• Top immunomodulators for rheumatoid arthritis and IBD
PART 06: Pipeline portfolio
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of disease
• Global rheumatoid arthritis immunomodulators market
• Global IBD immunomodulators market
PART 09: Market segmentation by molecule type
• Global autoimmune and inflammatory biologic immunomodulators market
• Global autoimmune and inflammatory small molecule immunomodulators market
PART 10: Geographical segmentation
• Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
• Autoimmune and inflammatory immunomodulators market in Americas
• Autoimmune and inflammatory immunomodulators market in EMEA
• Autoimmune and inflammatory immunomodulators market in APAC
PART 11: Market drivers
• Strong adoption of TNF-alpha inhibitors and B-cell inhibitors
• Development of novel therapies using innovative technologies
• Improved diagnostic tools increase the treatment-seeking population
PART 12: Impact of drivers
PART 13: Market challenges
• Discontinuation of drugs under development leading to substantial loss of revenue
• Growing popularity of alternative treatment procedures hinders the market growth
• Adverse effects of the drugs
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Emergence of oral agents likely to improve patient outcomes
• Advent of biosimilars expected to improve the treatment rates
• Focus on regenerative medicines
• Strategic alliances and acquisitions
PART 16: Vendor landscape
• Competitive scenario
• Other prominent vendors
PART 17: Key vendor analysis
• AbbVie
• Johnson & Johnson
• Amgen
• F. Hoffmann-La Roche
• Pfizer
PART 18: Appendix
• List of abbreviations
PART 19: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Different classes of immunosuppressant drugs based on their mechanism of action
Exhibit 03: Key buying criteria for global autoimmune and inflammatory immunomodulators market 2015
Exhibit 04: Key customer segments of autoimmune and inflammatory immunomodulators market
Exhibit 05: Etiology of autoimmune diseases
Exhibit 06: Pipeline portfolio: Rheumatoid arthritis immunomodulators
Exhibit 07: Pipeline portfolio: Ulcerative colitis immunomodulators
Exhibit 08: Pipeline portfolio: Crohn’s disease immunomodulators
Exhibit 09: Global autoimmune and inflammatory immunomodulators market snapshot: Developed and emerging markets 2015
Exhibit 10: Factors influencing global autoimmune and inflammatory immunomodulators market
Exhibit 11: Approval and patent expiries of top-selling biologics
Exhibit 12: Impact of factors affecting the market 2015 and 2020
Exhibit 13: Global autoimmune and inflammatory immunomodulators market 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Segmentation of global autoimmune and inflammatory immunomodulators by type of disease based on revenue 2015
Exhibit 16: Global autoimmune and inflammatory immunomodulators market by disease type 2015-2020
Exhibit 17: Global rheumatoid arthritis immunomodulators market 2015-2020 ($ billions)
Exhibit 18: Opportunities across rheumatoid arthritis industry
Exhibit 19: Global IBD immunomodulators market 2015-2020 ($ billions)
Exhibit 20: Global IBD therapeutics market segmentation growth lifecycle analysis
Exhibit 21: Global IBD immunomodulators market by disease type 2015-2020
Exhibit 22: Global ulcerative colitis immunomodulators market 2015-2020 ($ billions)
Exhibit 23: Global Crohn’s disease immunomodulators market 2015-2020 ($ billions)
Exhibit 24: Comparative graph of global autoimmune and inflammatory immunomodulators market by molecule type ($ billions)
Exhibit 25: Global autoimmune and inflammatory biologic immunomodulators market 2015-2020 ($ billions)
Exhibit 26: Biologicals approvals by the US FDA
Exhibit 27: Global rheumatoid arthritis biologic immunomodulators market 2015-2020 ($ billions)
Exhibit 28: Global IBD biologic immunomodulators market 2015-2020 ($ billions)
Exhibit 29: Global autoimmune and inflammatory small molecule immunomodulators market 2015-2020 ($ billions)
Exhibit 30: Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
Exhibit 31: Global autoimmune and inflammatory immunomodulators market segmentation by geography 2015-2020 ($ billions)
Exhibit 32: Global share of autoimmune and inflammatory immunomodulators market by geography 2015
Exhibit 33: Global autoimmune and inflammatory immunomodulators market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 34: Global autoimmune and inflammatory immunomodulators market: Country analysis based on revenue and growth rate
Exhibit 35: Opportunity analysis of autoimmune and inflammatory immunomodulators market in Americas
Exhibit 36: Autoimmune and inflammatory immunomodulators market in Americas 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of autoimmune and inflammatory immunomodulators market in EMEA
Exhibit 38: Autoimmune and inflammatory immunomodulators market in EMEA 2015-2020 ($ billions)
Exhibit 39: Opportunity analysis of autoimmune and inflammatory immunomodulators market in APAC
Exhibit 40: Autoimmune and inflammatory immunomodulators market in APAC 2015-2020 ($ billions)
Exhibit 41: Sales performance of key TNF-alpha inhibitors and B-cell inhibitors ($ billions)
Exhibit 42: Key vendors: Developing novel therapies
Exhibit 43: Key developments leading to improved diagnostics
Exhibit 44: Impact of drivers
Exhibit 45: List of few immunomodulators that were discontinued from development or market
Exhibit 46: CAM therapies for rheumatoid arthritis
Exhibit 47: Usage of CAM therapies in US adults
Exhibit 48: List of CAM therapies and items used in Crohn’s disease and ulcerative colitis
Exhibit 49: List of adverse side effects associated with rheumatoid arthritis
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Key marketed and pipeline oral agents
Exhibit 52: List of few biosimilars under development for various indications
Exhibit 53: List of few regenerative medicines under development for rheumatoid arthritis and IBD
Exhibit 54: Key deals in global immunomodulators market
Exhibit 55: Market share of key vendors 2015
Exhibit 56: Geographical presence of key vendors
Exhibit 57: Competitive scenario of global autoimmune and inflammatory immunomodulators market vendors 2015-2020
Exhibit 58: AbbVie: Strength assessment
Exhibit 59: AbbVie: Strategy assessment
Exhibit 60: AbbVie: Opportunity assessment
Exhibit 61: AbbVie: YoY growth and revenue of Humira 2013-2015 ($ billions)
Exhibit 62: Johnson & Johnson: Strength assessment
Exhibit 63: Johnson & Johnson: Strategy assessment
Exhibit 64: Johnson & Johnson: Opportunity assessment
Exhibit 65: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 66: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 67: Amgen: Strength assessment
Exhibit 68: Amgen: Strategy assessment
Exhibit 69: Amgen: Opportunity assessment
Exhibit 70: Amgen: YoY revenue and growth rate of Enbrel (in the US and Canada) 2013-2015 ($ billions)
Exhibit 71: F. Hoffmann-La Roche: Strength assessment
Exhibit 72: F. Hoffmann-La Roche: Strategy assessment
Exhibit 73: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan for immunology segment 2013-2015 ($ billions)
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue of Actemra/RoActemra for immunology segment 2013-2015 ($ billions)
Exhibit 76: Pfizer: Strength assessment
Exhibit 78: Pfizer: Strategy assessment
Exhibit 79: Pfizer: Opportunity assessment
Exhibit 80: Pfizer: Global autoimmune and inflammatory immunomodulators revenues 2014-2015 ($ billions)
【レポート販売概要】
■ タイトル：自己免疫および炎症性免疫調節剤の世界市場2016-2020■ 英文：Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020
■ 発行日：2016年11月3日
■ 調査会社：Technavio
■ 商品コード：IRTNTR10705
■ 調査対象地域：グローバル
- 魚雷の世界市場2017-2021About TorpedoTorpedoes are anti-submarine and anti-warship weapons used by navies across the globe with systems that are self-propelled and guided projectiles. These are operated mostly underwater and are designed to detonate on contact or in proximity to a target. Torpedoes may be launched from surface ships, submarines, fixed-wing aircraft, or helicopters. Torpedoes that are launched from warshi …
- 対IED（即席爆発装置）の世界市場2016-2020About Defense Counter IED Systems A counter improvised explosive device (C-IED) is an essential piece of equipment in battlefield operations. Battle tanks and mine-resistant and lightweight vehicles are some of the key systems to counter improvised explosive device (IED) threats. Modern-day warfare has also emphasized the use of electronic jammers and detection systems to prevent and locate explos …
- コールドチェーンの世界市場分析：タイプ別（ストレージ、輸送、監視コンポーネント）、用途別（フルーツ･野菜; 乳製品; 魚、肉、シーフード、加工食品、医薬品）、セグメント予測、2014-2025The global cold chain market is anticipated to reach USD 381.68 billion by 2025, according to a new report by Grand View Research, Inc. The expansion of trade over the years has arisen the necessity of making improvements in the packaging of crops as such, the materials used for packaging play a major role in enhancing the storage life. The development of cold chain is largely responsible for the …
- 企業向けファイル共有・同期（EFSS）アプリケーションの世界市場予測（～2020）The Enterprise File Sharing and Synchronization market size is expected to grow from USD 1.11 Billion in 2015 to USD 3.51 Billion by 2020, at a Compound Annual Growth Rate (CAGR) of 25.7%. Composed EFSS trend, demand for cloud-based integration, and Bring-Your-Own-Device (BYOD) adoption have enabled wider adoption of EFSS solutions among many industries. Companies are increasingly adopting EFSS so …
- B型肝炎ウイルス（HPV）治療市場：現在・未来プレイヤーHepatitis B Virus (HBV) Therapeutics - Current and Future Players Summary GlobalData has released its pharma report, “Hepatitis B Virus (HBV) Therapeutics - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HBV Market. The report identifies and analyses the key companies shaping and driving the global …
- 4G及び4G以後のスモールセルネットワーク導入戦略（Strategies for Small Cell Network Deployments for 4G and Beyond）Current smart phone usage trends indicate that there will be a huge increase in global mobile user traffic. In the next five years alone, the mobile user traffic is expected to reach 11.2 Exabyte per month. Small Cells and Small Cell Networks are expected to play a pivotal role in addressing the capacity needs for such a traffic surge in the mobile networks. Small Cells and Carrier WiFi are import …
- 2014年戦略提言：ロタウイルスの診断検査市場The report presents a detailed analysis of the Rotavirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Rotavirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Comm …
- 低温クーラーの世界市場：ギフォード・マクマホン冷凍機、パルス管冷凍機、スターリング冷凍機、ジュール・トムソン冷凍機、ブレイトン冷凍機The global cryocooler market is expected to grow from USD 1.76 Billion in 2015 to USD 2.94 Billion by 2022, at a CAGR of 7.29% between 2016 and 2022. The market is majorly driven by the growing medical & healthcare services in developing economies and rapid shortage of helium gas. In addition, factors such as growing demand for cryocoolers in space applications and development of cryocoolers for m …
- 咽頭新生物(Pharyngeal Neoplasm)：世界の治験レビュー（2015年上半期版）Pharyngeal Neoplasm Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Pharyngeal Neoplasm Global Clinical Trials Review, H1, 2015" provides data on the Pharyngeal Neoplasm clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pharyngeal Neoplasm. It includes an overview of the trial numbers and their recru …
- 産業用ギヤボックスの世界市場2016-2020About Industrial GearboxA gearbox is a mechanical box that transmits energy from one device to another to reduce speed and generate torque. A gearbox assembly includes various components such as gears, shafts, bearing covers, bearing keys, oil rings, and oil seals. Among all the industrial gearboxes available in the market, the planetary gearbox segment has seen a recent surge in demand due to inc …
- 味覚障害（Dysgeusia）：グローバル臨床試験レビュー（2014年上半期）Dysgeusia (Taste Disorders) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Dysgeusia (Taste Disorders) Global Clinical Trials Review, H1, 2014" provides data on the Dysgeusia (Taste Disorders) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dysgeusia (Taste Disorders). It includes an overview of t …
- 打楽器の世界市場2016-2020About Percussion Instruments Percussion instruments are musical instruments that produce sound due to vibrations. These instruments are categorized into idiophones that produce sounds due to vibrations on the surface of the instrument and membranophones that produce sounds due to vibrations on a stretched membrane, which include drums. These membranes are typically made of animal skin or plastics. …
- 建築外装用塗料の世界市場2015-2019About exterior architectural coatings Coatings are products used to protect a surface and/or enhance its appearance. Architectural coatings are applied to commercial and residential buildings. They protect a building from moisture, UV radiation, and microbes. Paints, primers, lacquers, varnishes, and stains are some of the primary types of architectural coating products. These are formulated using …
- 統合ネットワーク管理の世界市場：有線、無線The unified network management market is estimated to grow from USD 5.01 Billion in 2016 to USD 12.32 Billion by 2021. The market is expected to grow at an impressive Compound Annual Growth Rate (CAGR) of 19.7% owing to the rising usage of unified networking solutions among organizations to manage and control wireline or wireless networking activities. Companies are deploying unified networking so …
- 瘢痕治療の世界市場2016-2020About Scar Treatment A scar is a patch of fibrous tissue (containing a protein called collagen) that is formed over a wound as a consequence of the body's natural healing process. Scars are classified into keloid scars, contracture scars, hypertrophic scars, and atrophic scars based on the composition of collagen and appearance. Many non-invasive methods including chemical and physical treatment a …
